Table 4.
Associations of active vitamin B6 (pyridoxal-5’-phosphate) with inflammation biomarkers, stratified by BMI and cancer stage among 238 colorectal cancer patients enrolled in the ColoCare Study*
(β-Coefficients and 95 % confidence intervals)
| Inflammation biomarkers | WHO BMI category† |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Underweight/normal weight <25 kg/m2 (n 87) |
Overweight 25 to <30 kg/m2 (n 110) |
Obese 30+ kg/m2 (n 40) |
P for heterogeneity |
|||||||||
| β | 95 % CI | P | β | 95 % CI | P | β | 95 % CI | P | Under-/normal v. overweight | Under-/normal weight v. obese | Overall | |
| CRP | −1·45 | −2·26, −0·63 | 0·0008 | −0·54 | −1·02, −0·06 | 0·03 | −1·03 | −2·89, 0·82 | 0·25 | 0·02 | 0·52 | 0·07 |
| SAA | −1·21 | −1·90, −0·52 | 0·0009 | −0·34 | −0·82, 0·15 | 0·17 | −0·77 | −3·06, 1·53 | 0·48 | 0·03 | 0·29 | 0·0 |
| IL-8 | −0·48 | −0·85, −0·11 | 0·01 | −0·18 | −0·52, −0·16 | 0·29 | −0·33 | −1·17, 0·52 | 0·43 | 0·28 | 0·43 | 0·51 |
| IL-6 | −0·57 | −1·13, −0·02 | 0·04 | −0·65 | −1·07, −0·23 | 0·003 | −0·72 | −1·36, −0·08 | 0·03 | 0·94 | 0·56 | 0·83 |
| TNFα | −0·07 | −0·33, 0·20 | 0·61 | −0·13 | −0·32, 0·06 | 0·18 | −0·49 | −1·01, 0·03 | 0·06 | 0·61 | 0·28 | 0·36 |
| Inflammation biomarkers | Cancer stage† |
|||||||||||
| Stage I (n 57) |
Stage II (n 96) |
Stage III (n 85) |
P for heterogeneity |
|||||||||
| β | 95% CI | P | β | 95% CI | P | β | 95% CI | P | I v. II | I v. III | Overall | |
| CRP | −2·02 | −2·83, −1·19 | <0·0001 | −0·72 | −1·33, −0·11 | 0·02 | −0·44 | −1·18, 0·29 | 0·23 | 0·22 | 0·03 | 0·09 |
| SAA | −1·42 | −2·32, −0·52 | 0·003 | −0·49 | −1·08, 1·11 | 0·11 | −0·30 | −1·02, 0·42 | 0·41 | 0·39 | 0·32 | 0·58 |
| IL-8 | −0·58 | −1·15, −0·02 | 0·04 | −0·12 | −0·49, 0·25 | 0·52 | −0·32 | 0·71, 0·07 | 0·10 | 0·55 | 0·91 | 0·78 |
| IL-6 | −1·21 | −2·0, −0·44 | 0·003 | −0·54 | −0·92, −0·15 | 0·007 | −0·56 | −1·09, −0·02 | 0·04 | 0·05 | 0·15 | 0·14 |
| TNFα | −0·38 | −0·79, 0·02 | 0·06 | −0·17 | −0·43, 0·09 | 0·19 | −0·07 | −0·30, 0·15 | 0·52 | 0·35 | 0·26 | 0·51 |
CRP, C-reactive protein; SAA, serum amyloid A.
*
Biomarker values were log2-transformed to meet the normality assumptions for linear regression models.
†
Multivariable regression analysis adjusted for: age group (<60, 60 to <70 and ≥70 years), sex, BMI category, cancer stage and site, physical activity, multivitamin intake and smoking status.